In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72

David Colcher; Diane E. Milenic; Patrizia Ferroni; Mario Roselli; Jeffrey Schlom

doi:10.1016/0883-2897(91)90066-T

In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72

David Colcher, Diane E. Milenic, Patrizia Ferroni, Mario Roselli, Jeffrey Schlom

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Monoclonal antibodies against a tumor-associated antigen (TAG-72) with mucin-like properties have been generated. MAb B72.3 was used to identify and help characterize this antigen. B72.3 has been successfully used for the localization of tumor metastases in situ after i.v. administration. MAb B72.3 has also been used in conjunction with CC49, another anti-TAG-72 MAb, to measure TAG-72 levels in sera and effusions. TAG-72 can be found in the fluids of patients with adenocarcinomas from many different sites. This CA 72-4 double determinant radioimmunoassay in conjunction with assays for carcinoembryonic antigen can identify patients with malignancies with greater sensitivity than either assay alone.

Original language	English
Pages (from-to)	395-401
Number of pages	7
Journal	International Journal of Radiation Applications and Instrumentation.
Volume	18
Issue number	4
DOIs	https://doi.org/10.1016/0883-2897(91)90066-T
Publication status	Published - 1991

Access to Document

10.1016/0883-2897(91)90066-T

Cite this

@article{8cbe715b21d348bfb374e697cfe1fe76,

title = "In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72",

abstract = "Monoclonal antibodies against a tumor-associated antigen (TAG-72) with mucin-like properties have been generated. MAb B72.3 was used to identify and help characterize this antigen. B72.3 has been successfully used for the localization of tumor metastases in situ after i.v. administration. MAb B72.3 has also been used in conjunction with CC49, another anti-TAG-72 MAb, to measure TAG-72 levels in sera and effusions. TAG-72 can be found in the fluids of patients with adenocarcinomas from many different sites. This CA 72-4 double determinant radioimmunoassay in conjunction with assays for carcinoembryonic antigen can identify patients with malignancies with greater sensitivity than either assay alone.",

author = "David Colcher and Milenic, {Diane E.} and Patrizia Ferroni and Mario Roselli and Jeffrey Schlom",

year = "1991",

doi = "10.1016/0883-2897(91)90066-T",

language = "English",

volume = "18",

pages = "395--401",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72

AU - Colcher, David

AU - Milenic, Diane E.

AU - Ferroni, Patrizia

AU - Roselli, Mario

AU - Schlom, Jeffrey

PY - 1991

Y1 - 1991

N2 - Monoclonal antibodies against a tumor-associated antigen (TAG-72) with mucin-like properties have been generated. MAb B72.3 was used to identify and help characterize this antigen. B72.3 has been successfully used for the localization of tumor metastases in situ after i.v. administration. MAb B72.3 has also been used in conjunction with CC49, another anti-TAG-72 MAb, to measure TAG-72 levels in sera and effusions. TAG-72 can be found in the fluids of patients with adenocarcinomas from many different sites. This CA 72-4 double determinant radioimmunoassay in conjunction with assays for carcinoembryonic antigen can identify patients with malignancies with greater sensitivity than either assay alone.

AB - Monoclonal antibodies against a tumor-associated antigen (TAG-72) with mucin-like properties have been generated. MAb B72.3 was used to identify and help characterize this antigen. B72.3 has been successfully used for the localization of tumor metastases in situ after i.v. administration. MAb B72.3 has also been used in conjunction with CC49, another anti-TAG-72 MAb, to measure TAG-72 levels in sera and effusions. TAG-72 can be found in the fluids of patients with adenocarcinomas from many different sites. This CA 72-4 double determinant radioimmunoassay in conjunction with assays for carcinoembryonic antigen can identify patients with malignancies with greater sensitivity than either assay alone.

UR - http://www.scopus.com/inward/record.url?scp=44949285533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949285533&partnerID=8YFLogxK

U2 - 10.1016/0883-2897(91)90066-T

DO - 10.1016/0883-2897(91)90066-T

M3 - Article

C2 - 1864728

AN - SCOPUS:44949285533

SN - 0969-8051

VL - 18

SP - 395

EP - 401

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 4

ER -

In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72

Abstract

Access to Document

Other files and links

Fingerprint

Cite this